Product Description
McGill University is developing Enoxacin as a treatment for Amyotrophic Lateral Sclerosis (ALS). (Sourced from: https://www.clinicaltrials.gov/study/NCT04840823)
Mechanisms of Action: TOP2 Inhibitor,ATPase Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular,Intravenous,Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Egypt | Germany | India | Ireland | Morocco | New Zealand | Pakistan | Peru | Portugal | Taiwan | Turkey | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: McGill University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Canada
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Amyotrophic Lateral Sclerosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
REALS-1 | P2 |
Completed |
Amyotrophic Lateral Sclerosis |
2023-11-15 |